Utah Medical Products (UTMD) Cash & Equivalents (2010 - 2026)

Utah Medical Products' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $87.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 4.9% year-over-year to $87.4 million; the TTM figure through Mar 2026 stood at $87.4 million (up 4.9% YoY), while the FY2025 annual figure was $85.8 million, up 3.35% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $87.4 million, up from $85.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $93.8 million in Q1 2024, with the low at $65.9 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $84.3 million (2025), against an average of $82.4 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents rose 27.78% in 2023, then decreased 11.17% in 2025.
• Utah Medical Products' Cash & Equivalents stood at $75.1 million in 2022, then climbed by 23.74% to $92.9 million in 2023, then declined by 10.65% to $83.0 million in 2024, then grew by 3.35% to $85.8 million in 2025, then advanced by 1.92% to $87.4 million in 2026.
• Business Quant data shows UTMD's Cash & Equivalents at $87.4 million in Q1 2026, $85.8 million in Q4 2025, and $84.3 million in Q3 2025.